FrancophonIA/ELRC3.0 huggingface dataset:
English: Injecting the solution with an air bubble present is harmless.
Croatian: Injiciranje otopine s mjehurićima zraka ne predstavlja opasnost.
English: (Chondrocalcinosis Pyrophosphate) Fluid volume disturbances
Croatian: Pseudogiht a (pirofo sfatna hondrokalcinoza) Poremećaji volume na tekućine
English: Example: In a final injection volume of 20 ml, total doses of filgrastim less than 30 MU (300 g) should be given with 0.2 ml of 200 mg/ml (20%) human albumin solution added.
Croatian: Primjer: U konačni volumen injiciranja od 20 ml s ukupnom dozom filgrastima manjom od 30 MU (300 g) treba dodati 0,2 ml otopine ljudskog albumina koncentracije 200 mg/ml (20%-tna otopina).
English: How to use Nivestim
Croatian: Kako primjenjivati Nivestim
English: Example: In a final injection volume of 20 ml, total doses of filgrastim less than 30 MU (300 µg) should be given with 0.2 ml of 20% human albumin solution Ph. Eur.
Croatian: Primjer: u konačni volumen injiciranja od 20 ml, koji sadrži ukupnu dozu filgrastima manju od 30 MU (300 g), treba dodati 0,2 ml 20%-tne otopine ljudskog albumina (Ph. Eur.).
English: In a separate retrospective International study in patients with acute and chronic myelogenous leukaemias, no effect on the risk of GvHD, TRM and mortality was seen.
Croatian: U drugom retrospektivnom međunarodnom ispitivanju u bolesnika s akutnom ili kroničnom mijeloičnom leukemijom nije primijećen nikakav učinak na rizik razvoja GvHD, smrtnosti povezane s liječenjem (TRM) te smrtnosti općenito.
English: Data from clinical studies in paediatric patients indicate that the safety and efficacy of filgrastim are similar in both adults and children receiving cytotoxic chemotherapy.
Croatian: Podaci iz kliničkih ispitivanja u pedijatrijskih bolesnika pokazuju da su sigurnost i djelotvornost primjene filgrastima slične u odraslih i djece liječenih citotoksičnom kemoterapijom.
English: The no observed adverse effect level for embryo-foetal toxicity in this study was 10 µg/kg/day, which corresponded to a systemic exposure of approximately 3-5 times the exposures observed in patients treated with the clinical dose.
Croatian: U ovom ispitivanju doza od 10 g/kg/dan bila je razina pri kojoj nisu uočeni štetni učinci za embrio-fetalnu toksičnost, što odgovara sistemskoj izloženosti od oko 35 puta izloženosti uočene u bolesnika liječenih s kliničkim dozama.
English: Place the syringe into the sharps container.
Croatian: 13. Odložite štrcaljku u spremnik za oštre predmete.
English: Nivestim works by encouraging the bone marrow to produce more white blood cells.
Croatian: Nivestim djeluje poticanjem koštane srži na stvaranje većeg broja krvnih stanica.
English: Pre-filled syringe (type I glass), with injection needle (stainless steel) with a needle guard, containing 0.2 ml solution for injection/infusion.
Croatian: Napunjena štrcaljka (staklo tipa I) s iglom za injekciju (nehrđajući čelik) i štitnikom za iglu, koja sadrži 0,2 ml otopine za injekciju/infuziju.
English: Hyperuricaemia Blood uric acid increased
Croatian: Hiperuricemija Povišena razina mokraćne kiseline u krvi
English: In patients treated with myeloablative therapy followed by bone marrow transplantation
Croatian: U bolesnika koji primaju mijeloablativnu terapiju prije transplantacije koštane srži
English: Hepatomegaly Blood alkaline phosphatase increased
Croatian: Povišena alkalna fosfataza u krvi
English: Blood cell counts
Croatian: Broj krvnih stanica
English: The duration of fever was not reduced in patients undergoing myeloablative therapy followed by bone marrow transplantation.
Croatian: Trajanje vrućice nije se skratilo u bolesnika koji su primali mijeloablativnu terapiju prije presađivanja koštane srži.
English: Treatment with filgrastim alone does not preclude thrombocytopenia and anaemia due to myelosuppressive chemotherapy.
Croatian: Liječenje samim filgrastimom ne sprječava pojavu trombocitopenije i anemije uzrokovane mijelosupresivnom kemoterapijom.
English: Gammaglutamyl transferase increased
Croatian: Povišena gama glutamiltransfer aza
English: A detailed history with regard to HFI symptoms has to be taken of each patient prior to being given this medicinal product.
Croatian: Prije primjene ovog lijeka potrebno je od svakog bolesnika uzeti detaljnu anamnezu s obzirom na simptome nasljednog nepodnošenja fruktoze.
English: • inflammation of the lung (bronchitis)
Croatian: • upala pluća (bronhitis)
English: Filgrastim should be diluted in 20 ml of 5% glucose solution (see section 6.6).
Croatian: Filgrastim treba razrijediti u 20 ml 5%-tne otopine glukoze (vidjeti dio 6.6).
English: For infusions filgrastim should be diluted in 20 ml of 5% glucose solution (see section 6.6).
Croatian: Za infuzije filgrastim treba razrijediti u 20 ml 5%-tne otopine glukoze (vidjeti dio 6.6).
English: Treatment with filgrastim alone does not preclude thrombocytopenia and anaemia due to myelosuppressive medications.
Croatian: Primjena samog filgrastima ne sprječava pojavu trombocitopenije i anemije uzrokovane mijelosupresivnim lijekovima.
English: Complete blood cell counts with differential and platelet counts, and an evaluation of bone marrow morphology and karyotype should be performed prior to treatment.
Croatian: Prije početka primjene lijeka treba napraviti kompletnu i diferencijalnu krvnu sliku, odrediti broj trombocita, evaluirati morfologiju koštane srži i obaviti kariotipizaciju.
English: Needle guard is attached to the pre-filled syringe in order to protect from needle stick injury.
Croatian: Štitnik za iglu je pričvršćen na napunjenu štrcaljku kako bi se spriječile ozljede ubodom igle.
English: Blood lactate dehydrogenase increased
Croatian: Smanjen apetit Povišena laktat dehidrogenaza u krvi
English: • generally feeling unwell (malaise)
Croatian: • opće loše osjećanje (malaksalost)
English: Pregnancy and breast-feeding
Croatian: Trudnoća, dojenje i plodnost
English: Make sure you have your sharps container nearby.
Croatian: Vodite računa da Vam spremnik za odlaganje oštrih predmeta bude pri ruci.
English: The recommended dose of filgrastim for PBPC mobilisation when used alone is 1.0 MU (10 µg)/kg/day for 5 to 7 consecutive days.
Croatian: Kad se daje sam, preporučena doza filgrastima za mobilizaciju KMSPK je 1,0 MU (10 µg)/kg/dan tijekom 5 do 7 uzastopnih dana.
English: Regular monitoring of platelet count and haematocrit is recommended.
Croatian: Preporučuju se redovite kontrole trombocita i hematokrita.
English: Cutaneous vasculitis has been reported in patients treated with filgrastim.
Croatian: Kutani vaskulitis zabilježen je u bolesnika liječenih filgrastimom.
English: For the mobilisation of PBPCs in normal donors prior to allogeneic PBPC transplantation
Croatian: Za mobilizaciju KMSPK u zdravih davatelja prije presađivanja alogenih KMSPK
English: In patients with known bone marrow infiltrating infections or malignancy, consider appropriate therapy for treatment of the underlying condition, in addition to administration of filgrastim for treatment of neutropenia.
Croatian: U bolesnika s poznatom infiltracijom uzročnicima infekcije ili zloćudnom bolešću valja, povrh primjene filgrastima za korekciju leukopenije, razmotriti i primjenu prikladnog lijeka za liječenje stanja u podlozi.
English: Nivestim is not recommended during pregnancy.
Croatian: Ne preporučuje se koristiti lijek Nivestim tijekom trudnoće.
English: For the mobilisation of PBPCs in patients undergoing myelosuppressive or myeloablative therapy followed by autologous PBPC transplantation
Croatian: Za mobilizaciju krvotvornih matičnih stanica periferne krvi (KMSPK) u bolesnika koji primaju mijelosupresivnu ili mijeloablativnu terapiju nakon koje slijedi transplantacija autolognih matičnih stanica periferne krvi
English: • decrease of platelets which reduces the ability of blood to clot (thrombocytopenia)
Croatian: • pad broja trombocita, što smanjuje sposobnost zgrušavanja krvi (trombocitopenija)
English: Use of filgrastim for the mobilisation of PBPCs in normal donors prior to allogeneic PBPC transplantation
Croatian: Primjena filgrastima za mobilizaciju KMSPK-a u zdravih davatelja prije alogene transplantacije KMSPK-ova.
English: Pre-filled syringe (type I glass), with injection needle (stainless steel) with a needle guard, containing 0.5 ml solution for injection/infusion
Croatian: Napunjena štrcaljka (staklo tipa I) s iglom za injekciju (nehrđajući čelik) i štitnikom za iglu, koja sadrži 0,5 ml otopine za injekciju/infuziju.
English: A faster schedule of dose escalation may be considered in patients presenting with severe infections.
Croatian: U bolesnika s teškim infekcijama može se razmotriti brže podizanje doze.
English: Dilution to a final concentration less than 0.2 MU (2 µg) per ml is not recommended at any time.
Croatian: Ne preporučuje se razrjeđivanje do konačne koncentracije manje od 0,2 MU (2 g) po mililitru.
English: The safety and efficacy of filgrastim have not been assessed in normal donors < 16 years or > 60 years.
Croatian: Sigurnost i djelotvornost primjene filgrastima u zdravih davatelja mlađih od 16 i starijih od 60 godina nisu ispitane.
English: Hypersensitivity Drug hypersensitivity a
Croatian: Preosjetljivost Preosjetljivost n a lijek
English: Uncommon (≥ 1/1,000 to
Croatian: Manje često (≥ 1/1000 i
English: Pulmonary adverse effects, in particular interstitial lung disease, have been reported after G-CSF administration.
Croatian: Nakon primjene G-CSF-a zabilježene su plućne nuspojave, osobito intersticijska plućna bolest.
English: Among these, two cases of platelets < 50 x 10
Croatian: Među njima su i dva slučaja s tromobocitima <50 x 10 9/l, što je pripisano postupku leukafereze.
English: In some SCN patients filgrastim can also induce a minor increase in the number of circulating eosinophils and basophils relative to baseline; some of these patients may present with eosinophilia or basophilia already prior to treatment.
Croatian: U nekih SCN bolesnika filgrastim može inducirati i neznatan porast broja eozinofila i bazofila u cirkulaciji u odnosu na početne vrijednosti.
English: Hypoxia
Croatian: Hipoksija
English: 9/L) following filgrastim administration and leukapheresis was observed in 35% of subjects studied.
Croatian: Prolazna trombocitopenija (trombociti <100 x 10 9/l) nakon primjene filgrastima i leukafereze zabilježena je u 35% ispitanika.
English: Further dose adjustment may be necessary, as determined by the patient's ANC, to maintain the neutrophil count at > 2.0 x 10
Croatian: Može biti potrebno daljnje prilagođavanje doze za održavanje broja neutrofila na razini >2,0 x 9/l, određeno na temelju apsolutnog broja bolesnikovih neutrofila.
English: Premature discontinuation of filgrastim therapy, prior to the time of the expected neutrophil nadir, is not recommended.
Croatian: Ne preporučuje se prerana obustava filgrastima, prije postizanja očekivane najniže vrijednosti broja neutrofila.
English: • Nivestim 48 MU/0.5 ml solution for injection/infusion: each pre-filled syringe contains 48 million units (MU), 480 g of filgrastim in 0.5 ml (corresponding to 0.96 mg/ml).
Croatian: • Nivestim 48 MU/0,5 ml otopina za injekciju/infuziju: jedna napunjena štrcaljka sadrži 48 milijuna jedinica (MU), 480 g filgrastima u 0,5 ml otopine (što odgovara 0,96 mg/ml).
English: Special precautions in sickle cell trait and sickle cell disease
Croatian: Posebne mjere opreza kod nasljednog obilježja srpastih stanica i bolesti srpastih stanica
English: If you have any further questions on the use of this product, ask your doctor, nurse or pharmacist.
Croatian: U slučaju bilo kakvih pitanja u vezi s primjenom ovog lijeka, obratite se liječniku, medicinskoj sestri ili ljekarniku.
English: • lack of absorption of oxygen in the lung (hypoxia)
Croatian: • smanjen unos (apsorpcija) kisika kroz pluća (hipoksija)
English: Daily dosing with filgrastim should continue until the expected neutrophil nadir is passed and the neutrophil count has recovered to the normal range.
Croatian: Dnevna primjena filgrastima treba se nastaviti sve dok ne prođe vrijeme očekivane najniže vrijednosti broja neutrofila i dok se njihov broj ne normalizira.
English: Includes bone pain, back pain, arthralgia, myalgia, pain in extremity, musculoskeletal pain, musculoskeletal chest pain, neck pain.
Croatian: Uključuje bol u kostima, bol u leđima, artralgiju, mialgiju, bol u ekstremitetima, bol u mišićima i kostima, bol u mišićima i kostima prsiju, bol u vratu.
English: Following established chemotherapy for solid tumours, lymphomas, and lymphoid leukaemia, it is expected that the duration of treatment required to fulfil these criteria will be up to 14 days.
Croatian: Očekuje se da će primjena filgrastima nakon uobičajene kemoterapije za solidne tumore, limfome i leukemiju trajati do 14 dana.
English: • bleeding from the lung (pulmonary haemorrhage)
Croatian: • krvarenje iz pluća (plućno krvarenje)
English: Nivestim 48 MU/0.5 ml solution for injection/infusion Each ml of solution for injection or infusion contains 96 million units [MU] (960 micrograms [µg]) of filgrastim*.
Croatian: Nivestim 48 MU/0,5 ml otopina za injekciju/infuziju Jedan ml otopine za injekciju ili infuziju sadrži 96 milijuna jedinica [MU] (960 mikrograma [µg]) filgrastima*.
English: Posology
Croatian: Publikacija
English: 9/L) following filgrastim and leukapheresis was observed in
Croatian: 9/l) u 35% davatelja nakon primjene filgrastima i leukafereze
English: SYRINGE LABEL
Croatian: NALJEPNICA ŠTRCALJKE
English: Exacerbation of rheumatoid arthritis
Croatian: Egzacerbacija reumatoidnog artritisa
English: 9/L, with the median dose frequency being 3 days per week.
Croatian: 9/l bila potrebna doza od 30 MU (300 µg)/dan tijekom 1 do 7 dana na tjedan, s medijanom broja doza od 3 na tjedan.
English: • Nivestim 12 MU/0.2 ml solution for injection/infusion: each pre-filled syringe contains 12 million units (MU), 120 g of filgrastim in 0.2 ml (corresponding to 0.6 mg/ml).
Croatian: • Nivestim 12 MU/0,2 ml otopina za injekciju/infuziju: jedna napunjena štrcaljka sadrži 12 milijuna jedinica (MU), 120 g filgrastima u 0,2 ml otopine (što odgovara 0,6 mg/ml).
English: Information on self administration by the patient
Croatian: Upute za bolesnika o samoprimjeni
English: > 1.0 x 10 9/L for 3 consecutive days
Croatian: Potom, ako ABN ostane > 1,0 x 10 9/l tijekom najmanje 3 uzastopna dana
English: Veno-occlusive disease d
Croatian: Venookluzivna bolestd
English: 5 pre-filled syringes with 0.2 ml 8 pre-filled syringes with 0.2 ml 10 pre-filled syringes with 0.2 ml.
Croatian: Otopina za injekciju/infuziju 1 napunjena štrcaljka s 0,2 ml 5 napunjenih štrcaljki s 0,2 ml 8 napunjenih štrcaljki s 0,2 ml 10 napunjenih štrcaljki s 0,2 ml
English: There have been reports of GvHD and fatalities in patients receiving G-CSF after allogeneic bone marrow transplantation (see sections 4.4 and 5.1).
Croatian: U bolesnika koji su primali G-CSF nakon alogene transplantacije koštane srži zabilježeni su slučajevi GvHD-a i smrtni ishodi (vidjeti dijelove 4.4 i 5.1).
English: Special precautions in patients undergoing PBPC mobilisation
Croatian: Posebne mjere opreza u bolesnika u kojih se mobiliziraju KMSPK-ovi
English: Sickle cell anaemia with crisis
Croatian: Ruptura slezene Anemija srpastih stanica s krizom
English: 6.6 Special precautions for disposal
Croatian: 6.6 Posebne mjere za zbrinjavanje lijeka
English: Leucocytosis
Croatian: Leukocitoza
English: • Nivestim 30 MU/0.5 ml solution for injection/infusion: each pre-filled syringe contains 30 million units (MU), 300 g of filgrastim in 0.5 ml (corresponding to 0.6 mg/ml).
Croatian: • Nivestim 30 MU/0,5 ml otopina za injekciju/infuziju: jedna napunjena štrcaljka sadrži 30 milijuna jedinica (MU), 300 g filgrastima u 0,5 ml otopine (što odgovara 0,6 mg/ml).
English: There is insufficient data to evaluate filgrastim use in geriatric subjects for other approved filgrastim indications.
Croatian: Za druge odobrene indikacije filgrastima podaci nisu dostatni za procjenu primjene filgrastima u starijih ispitanika.
English: Pre-filled syringe
Croatian: Plućne nuspojave
English: Special precautions in normal donors undergoing PBPC mobilisation
Croatian: Posebne mjere opreza u zdravih davatelja u kojih se mobiliziraju KMSPK
English: Permanently discontinue filgrastim in patients with clinically significant hypersensitivity.
Croatian: U bolesnika s klinički značajnom preosjetljivošću trajno se prekida primjena filgrastima.
English: Established cytotoxic chemotherapy
Croatian: Standardna citotoksična kemoterapija
English: Oropharyngeal pain a,e
Croatian: Orofaringealna bol a,e
English: 9/L) was observed in 41% of normal donors and transient thrombocytopenia (platelets < 100 x 10
Croatian: Leukocitoza (broj bijelih krvnih stanica > 50 x 109/l) uočena je u 41% zdravih davatelja, a prolazna trombocitopenija (trombociti < 100 x 10
English: How do I administer my Nivestim?
Croatian: Kako sam sebi dati Nivestim?
English: Assessment of progenitor cell yields
Croatian: Procjena prinosa krvotvornih matičnih stanica
English: Use of UltraSafe Passive Needle Guard for Nivestim 30 MU/0.5 ml solution for injection/infusion and Nivestim 48 MU/0.5 ml solution for injection/infusion
Croatian: Uporaba pasivnog ultrasigurnog štitnika igle za Nivestim 30 MU/0,5 ml otopinu za injekciju/infuziju i Nivestim 48 MU/0,5 ml otopinu za injekciju/infuziju
English: Nivestim 12 MU/0.2 ml solution for injection/infusion Each ml of solution for injection or infusion contains 60 million units [MU] (600 micrograms [µg]) of filgrastim*.
Croatian: Nivestim 12 MU/0,2 ml otopina za injekciju/infuziju Jedan ml otopine za injekciju ili infuziju sadrži 60 milijuna jedinica [MU] (600 mikrograma [µg]) filgrastima*.
English: • generalised weakness (asthenia)
Croatian: • opća slabost (astenija)
English: The use of filgrastim-mobilised PBPCs has been shown to reduce the depth and duration of thrombocytopenia following myelosuppressive or myeloablative chemotherapy.
Croatian: Pokazalo se da krvotvorne matične stanice periferne krvi, mobilizirane filgrastimom, smanjuju dubinu i skraćuju trajanje trombocitopenije nakon mijelosupresivne ili mijeloablativne kemoterapije.
English: 35% of donors (see section 4.4).
Croatian: (vidjeti dio 4.4).
English: Each pre-filled syringe contains 48 million units (MU) (480 micrograms [µg]) of filgrastim in 0.5 ml (0.96 mg/ml).
Croatian: Jedna napunjena štrcaljka sadrži 48 milijuna jedinica (MU) (480 mikrograma [µg]) filgrastima u 0,5 ml (0,96 mg/ml).
English: • urinary tract infection
Croatian: • infekcija mokraćnog sustava
English: Nivestim 30 MU/0.5 ml solution for injection/infusion Each ml of solution for injection or infusion contains 60 million units [MU] (600 micrograms [µg]) of filgrastim*.
Croatian: Nivestim 30 MU/0,5 ml otopina za injekciju/infuziju Jedan ml otopine za injekciju ili infuziju sadrži 60 milijuna jedinica [MU] (600 mikrograma [µg]) filgrastima*.
English: Each pre-filled syringe contains 48 million units (MU) (480 g) of filgrastim in 0.5 ml (0.96 mg/ml)
Croatian: Jedna napunjena štrcaljka sadrži 48 milijuna jedinica (MU) (480 g) filgrastima u 0,5 ml otopine (0,96 mg/ml)
English: There was a low frequency (approximately 3%) of myelodysplastic syndromes (MDS) or leukaemia in clinical trial patients with SCN treated with filgrastim.
Croatian: U kliničkim ispitivanjima bolesnika sa SCN-om koji su primali filgrastim, zabilježena je niska učestalost (oko 3%) mijelodisplastičnog sindroma (MDS) ili leukemije.
English: Nivestim contains sodium
Croatian: Nivestim sadrži natrij
English: Immunogenicity
Croatian: Hepatomegalija
English: Upper respiratory tract infection
Croatian: Infekcija gornjeg dijela dišnog sustava Infekcija mokraćnog sustava
English: Nivestim 48 MU/0.5 ml injection/infusion filgrastim
Croatian: Nivestim 48 MU/0,5 ml otopina za injekciju/infuziju filgrastim
English: Dilution to a final concentration less than 0.2 MU (2 g) per ml is not recommended at any time.
Croatian: Ne preporučuje se razrjeđivanje lijeka do koncentracije niže od 0,2 MU (2 g) po ml.
English: • nose bleeds (epistaxis)
Croatian: • krvarenje iz nosa (epistaksa)
English: Prior exposure to cytotoxic agents
Croatian: Prethodna izloženost citotoksičnim lijekovima
English: Consideration should be given to temporary discontinuation or dose reduction of filgrastim in patients with severe chronic neutropenia who develop thrombocytopenia (platelet count < 100 x 10
Croatian: U bolesnika sa SCN-om koji razviju trombocitopeniju (broj trombocita < 100 x 10
English: Monitoring of bone density may be indicated in patients with underlying osteoporotic bone diseases who undergo continuous therapy with filgrastim for more than 6 months.
Croatian: U bolesnika s osteoporozom kao podležećom bolešću kostiju, koji primaju filgrastim dulje od 6 mjeseci, može biti indicirano praćenje gustoće kosti.
English: Depress the plunger while grasping the finger flange until the entire dose has been given.
Croatian: Potisnite klip dok ne ubrizgate cijelu dozu.
English: Nivestim 12 MU/0.2 ml solution for injection/infusion
Croatian: Nivestim 12 MU/0,2 ml otopina za injekciju/infuziju
English: Each pre-filled syringe contains 12 million units (MU) (120 micrograms [µg]) of filgrastim in 0.2 ml (0.6 mg/ml).
Croatian: Jedna napunjena štrcaljka sadrži 12 milijuna jedinica (MU) (120 mikrograma [µg]) filgrastima u 0,2 ml (0,6 mg/ml).
English: Each pre-filled syringe contains 30 million units (MU) (300 micrograms [µg]) of filgrastim in 0.5 ml (0.6 mg/ml).
Croatian: Jedna napunjena štrcaljka sadrži 30 milijuna jedinica (MU) (300 mikrograma [µg]) filgrastima u 0,5 ml (0,6 mg/ml).
English: Nivestim 12 MU/0.2 ml solution for injection/infusion Nivestim 30 MU/0.5 ml solution for injection/infusion Nivestim 48 MU/0.5 ml solution for injection/infusion filgrastim
Croatian: Nivestim 12 MU/0,2 ml otopina za injekciju/infuziju Nivestim 30 MU/0,5 ml otopina za injekciju/infuziju Nivestim 48 MU/0,5 ml otopina za injekciju/infuziju filgrastim
English: Dysuria Haematuria
Croatian: Mišićnokoštana bol
English: Pseudogout (chondrocalcinosis pyrophosphate) has been reported in patients with cancer treated with filgrastim.
Croatian: U bolesnika s rakom liječenih filgrastimom prijavljen je pseudogiht (pirofosfatna hondrokalcinoza).
English: Nivestim 30 MU/0.5 ml injection/infusion filgrastim
Croatian: Nivestim 30 MU/0,5 ml otopina za injekciju/infuziju filgrastim
English: Hypersensitivity, including anaphylactic reactions, occurring on initial or subsequent treatment have been reported in patients treated with filgrastim.
Croatian: U bolesnika liječenih filgrastimom zabilježeni su slučajevi preosjetljivosti, uključujući anafilaktičke reakcije, na početku liječenja ili kasnije tijekom liječenja.
English: Nivestim 12 MU/0.2 ml injection/infusion filgrastim
Croatian: Nivestim 12 MU/0,2 ml otopina za injekciju/infuziju filgrastim
English: Long term administration may be required to maintain the ANC > 2.0 x 10
Croatian: Za održavanje ABN na vrijednostima >2,0 x 10
English: Each pre-filled syringe contains 12 million units (MU) (120 g) of filgrastim in 0.2 ml (0.6 mg/ml)
Croatian: Jedna napunjena štrcaljka sadrži 12 milijuna jedinica (MU) (120 g) filgrastima u 0,2 ml otopine (0,6 mg/ml)
English: Пфайзер Люксембург САРЛ, Клон
Croatian: Pfizer Luxembourg SARL filialas Lietuvoje Tel.
English: Each pre-filled syringe contains 30 million units (MU) (300 g) of filgrastim in 0.5 ml (0.6 mg/ml)
Croatian: Jedna napunjena štrcaljka sadrži 30 milijuna jedinica (MU) (300 g) filgrastima u 0,5 ml otopine (0,6 mg/ml)
English: • pain when passing urine (dysuria)
Croatian: • bol kod mokrenja (dizurija)
English: Thrombocytopenia Anaemia e
Croatian: Trombocitopen ija
English: Nivestim 12 MU/0.2 ml solution for injection/infusion Nivestim 30 MU/0.5 ml solution for injection/infusion Nivestim 48 MU/0.5 ml solution for injection/infusion
Croatian: Nivestim 12 MU/0,2 ml otopina za injekciju/infuziju Nivestim 30 MU/0,5 ml otopina za injekciju/infuziju Nivestim 48 MU/0,5 ml otopina za injekciju/infuziju
English: Dizziness Hypoaesthesia Paraesthesia
Croatian: Omaglica Hipoestezija
English: • upper respiratory tract infection
Croatian: • infekcija gornjeg dijela dišnog sustava
English: • coughing up blood (haemoptysis)
Croatian: • iskašljavanje krvi (hemoptiza)
English: • muscle spasm
Croatian: • omaglica